http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 09 Apr 2025 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Press+Releases/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avicedarx.com%2F&amp;esheet=54235747&amp;newsitemid=20250409496616&amp;lan=en-US&amp;anchor=Aviceda+Therapeutics&amp;index=1&amp;md5=59a676bb6d6acb2587a220bd750ca5d2" shape="rect">Aviceda Therapeutics</a> (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. </p><p> Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment http://www.streetinsider.com/Business+Wire/Aviceda+Therapeutics+Appoints+Ophthalmology+Innovator+and+Industry+Leader+Dr.+Emmett+T.+Cunningham%2C+Jr.+to+Board+of+Directors/24617670.html Wed, 09 Apr 2025 07:00:00 -0400 A.03295816 A.08435063 A.11608963 A.12359475 A.50203644 ANNX GRAY LUMO O.00046891 O.05010326 O.12845549 O.21040684 http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++LUMOS+PHARMA%2C+INC.+++++++++++++++++++/24135759.html si-local-file:///var/storage/secattach/20241223/24135759.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++LUMOS+PHARMA%2C+INC.+++++++++++++++++++/24135759.html Mon, 23 Dec 2024 08:00:00 -0400 LUMO O.01686648